U.S. Global Investors Continues GROW Dividends San

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
37
U.S. Global Investors Continues GROW Dividends

San Antonio, Texas, Oct. 04, 2017 (GLOBE NEWSWIRE) -- U.S. Global Investors, Inc. ( NASDAQ : GROW ), a boutique registered investment advisory firm with longstanding experience in global markets and specialized sectors, will continue its payment of monthly dividends in the second fiscal quarter of 2018.

The company’s board of directors approved payment of the $0.0025 per share per month dividend beginning in October 2017 and continuing through December 2017. The record dates are October 16, November 13 and December 12, and the payment dates will be October 30, November 27 and December 26.

At the end of this period, the company will have paid monthly dividends for more than 10 years. At the October 3, 2017, closing price of $2.24, the $0.0025 monthly dividend equals a 1.34 percent yield on an annualized basis.

The continuation of future cash dividends will be determined by U.S. Global’s board of directors, at its sole discretion, after review of the company's financial performance and other factors, and is dependent on earnings, operations, capital requirements, general financial condition of the company and general business conditions.

About U.S. Global Investors, Inc.

The story of U.S. Global Investors goes back more than 40 years when it began as an investment club. Today, U.S. Global Investors, Inc. ( www.usfunds.com ) is a registered investment adviser that focuses on niche markets around the world. Headquartered in San Antonio, Texas, the Company provides money management and other services to U.S. Global Investors Funds, U.S. Global ETFs and other international clients.

# # # # #

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/Attachm...8d7ac189c5

Holly Schoenfeldt U.S. Global Investors, Inc. 210.308.1268 hschoenfeldt@usfunds.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Triumph Financial Sets Stage for Q4 Earnings and Insights

Updated Category News Views 196

Triumph Financial Plans Fourth Quarter Earnings Release Triumph Financial, Inc. (Nasdaq: TFIN) recently announced its anticipation for the release of fourth quarter financial results. This event is scheduled to take place after the market closes on an upcoming Wednesday. Along with the financial report, the company will provide management commentary for stakeholders and...

Continue Reading
Monitoring ABA Therapy Progress: A Parent's Guide

Updated Category News Views 6

The Nuts and Bolts of Progress Monitoring You've got a situation in Leominster where parents are trying to make sense of ABA therapy's impact on their kids. Rob Shapiro, a big name in the ABA world, breaks it all down in a HelloNation article. We're talking about precise data collection being the backbone of measuring progress in ABA therapy. This ain't no place for...

Continue Reading
Understanding Dowlais Group's Recent Market Activities

Updated Category News Views 185

Public Disclosure Regarding Dowlais Group's Trading Activity FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code 1. KEY INFORMATION (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree in relation to whose r

Continue Reading
OFS Credit Company Reports Impressive Q4 Financials for 2024

Updated Category News Views 98

OFS Credit Company Delivers Strong Q4 2024 Financial Results OFS Credit Company, Inc. (NASDAQ: OCCI), a notable investment firm focusing on collateralized loan obligation (CLO) equity and debt securities, has announced its financial performance for the fiscal quarter ending October 31, 2024. This report outlines the company’s significant financial growth and strategic...

Continue Reading
Breakthrough Data on HBI-8000 and Nivolumab for Melanoma

Updated Category News Views 89

HBI-8000 and Nivolumab: A New Era in Melanoma Treatment Recent findings highlight the potential of HBI-8000 in combination with nivolumab, suggesting a transformative approach in the treatment of advanced melanoma. This promising combination will be discussed in detail at an upcoming prestigious annual meeting focused on advancements in immunotherapy. Innovative Solutions...

Continue Reading